1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow EB-DART-NK01: new trials by email Literature Review of EB-DART-NK01 trials Research Report on EB-DART-NK01
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) EB-DART-NK01, Lymphodepleting chemotherapy - Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-03-02 | 2026-08-04 |
Recurrence (1) · Small Cell Lung Carcinoma (1)
Beijing Biotech (1)
China (1)